Related Experiment Video

Updated: Sep 27, 2026

Detection of Inter-chromosomal Stable Aberrations by Multiple Fluorescence In Situ Hybridization (mFISH) and Spectral Karyotyping (SKY) in Irradiated Mice
10:14

Detection of Inter-chromosomal Stable Aberrations by Multiple Fluorescence In Situ Hybridization (mFISH) and Spectral Karyotyping (SKY) in Irradiated Mice

Published on: January 11, 2017

Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate

C Schoch, T Haferlach, W Kern

    Leukemia
    |February 20, 2003
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
    10:09

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

    Published on: January 7, 2019

    Related Experiment Videos

    Last Updated: Sep 27, 2026

    Detection of Inter-chromosomal Stable Aberrations by Multiple Fluorescence In Situ Hybridization (mFISH) and Spectral Karyotyping (SKY) in Irradiated Mice
    10:14

    Detection of Inter-chromosomal Stable Aberrations by Multiple Fluorescence In Situ Hybridization (mFISH) and Spectral Karyotyping (SKY) in Irradiated Mice

    Published on: January 11, 2017

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
    10:09

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

    Published on: January 7, 2019

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Rehabilitation after surgical release of the stiff elbow: A literature review.

    Journal of orthopaedics·2024

    The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.

    Leukemia·2023

    [Interdisciplinary COVID board for patients with SARS-CoV-2-triggered hyperferritinemic Inflammation].

    Medizinische Klinik, Intensivmedizin und Notfallmedizin·2020

    The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.

    Leukemia·2020

    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

    Leukemia·2020

    [Surgical treatment of snapping triceps syndrome].

    Operative Orthopadie und Traumatologie·2019

    KT-253, a highly potent and selective MDM2 protein degrader, eliminates malignant myelofibrosis stem/progenitor cells.

    Leukemia·2026

    Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry.

    Leukemia·2026

    Chronic myeloid leukemia in a global context: confirmatory findings and novel discoveries from a refined Japanese Cohort.

    Leukemia·2026

    Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

    Leukemia·2026

    MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma.

    Leukemia·2026

    First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.

    Leukemia·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us